Forty-two years after approving the potent diuretic Bumex (bumetanide) as both an oral and infused treatment for edema, the FDA has endorsed a new version of the drug to be delivered as a nasal spray. The U.S. regulator has signed
read more
Positive orphan drug opinion supports SOM3355’s potential as first-line treatment in Europe More: SOM Biotech receives EMA backing for Huntington’s disease drug Source: News
read moreWhile the tone was often reflective at this year’s Fierce Pharma Week proceedings in Philadelphia, a sense of resilience and commitment to the critical work pharma communications and marketing teams do resonated throughout the event. More: From the press box:
read moreFDA Commissioner Marty Makary, M.D., took aim at drugmakers, online pharmacies and social media influencers in a new op-ed shedding more light on the Trump administration’s recent moves to rein in direct-to-consumer drug advertisements. More: FDA's Marty Makary deems DTC
read moreMore than 40 years after establishing the first U.S. pharmaceutical joint venture in China, Bristol Myers Squibb is handing over its controlling stake in the business. More: BMS sells controlling stake in historic US-China pharmaceutical joint venture Source: fierce
read moreIn a Fierce Pharma Week panel, experts including Coalition for Healthcare Communication Director James Potter discussed why President Donald Trump’s threats to drug advertising may be more bark than bite. More: 'Keep doing what you're doing': Marketing policy experts unfazed
read more© 1994 - 2026 B.M. Pharmaceuticals